Donath M J, de Laaf R T, Biessels P T, Lenting P J, van de Loo J W, van Mourik J A, Voorberg J, Mertens K
Department of Blood Coagulation, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands.
Biochem J. 1995 Nov 15;312 ( Pt 1)(Pt 1):49-55. doi: 10.1042/bj3120049.
A factor VIII variant has been characterized in which the heavy chain is directly fused to the light chain. Des-(741-1668)-factor VIII lacks the processing site at Arg1648, as Arg740 of the heavy chain is fused to Ser1669 of the light chain. The sequence of the fusion site is similar to that of other cleavage sites in factor VIII. The fusion site of des-(741-1668)-factor VIII was readily cleaved by both thrombin and factor Xa, and the same result was obtained for heavy chain cleavage. In contrast, des-(741-1668)-factor VIII cleavage by thrombin at position Arg1689 proceeded at a lower rate than the analogous cleavage by factor Xa, which presumably takes place at position Arg1721. The rate of cleavage at position Arg1689 by thrombin was also lower than that at the other processing sites. When des-(741-1668)-factor VIII was activated by thrombin, initial rates of factor Xa formation were similar to the rates obtained when plasma-derived factor VIII was activated by thrombin or factor Xa. Remarkably, activation of des-(741-1668)-factor VIII proceeded at a higher rate by factor Xa than by thrombin. These results indicate that factor VIII activation is strongly associated with cleavage at position Arg1689 or Arg1721. For the interaction between des-(741-1668)-factor VIII and von Willebrand factor, a Kd value of (0.8 +/- 0.3) x 10(-10) M was determined, which is similar to that of heterodimeric factor VIII. The affinity of single-chain des-(741-1668)-factor VIII for factor IXa was found to be 27 +/- 6 nM. The in vivo recovery and half-life of des-(741-1668)-factor VIII were assessed in guinea pigs. Upon infusion of des-(741-1668)-factor VIII at a dosage of 50 units/kg body weight, a rise of 1.0 +/- 0.3 unit/ml in factor VIII activity was obtained. The same recovery was determined for wild-type factor VIII. The half-life of des-(741-1668)-factor VIII was found to be 3 +/- 1 h, compared with 4 +/- 2 h for heterodimeric recombinant factor VIII. In conclusion, des-(741-1668)-factor VIII displays normal activity, is readily cleaved by thrombin and factor Xa at its fusion site, binds with high affinity to von Willebrand factor and factor IXa, and behaves like heterodimeric recombinant factor VIII in guinea pigs. By virtue of these properties, des-(741-1668)-factor VIII may prove useful for the treatment of bleeding episodes in patients with haemophilia A.
已鉴定出一种VIII因子变体,其中重链直接与轻链融合。缺失(741 - 1668)的VIII因子(des-(741-1668)-factor VIII)在精氨酸1648处缺乏加工位点,因为重链的精氨酸740与轻链的丝氨酸1669融合。融合位点的序列与VIII因子中其他切割位点的序列相似。des-(741-1668)-factor VIII的融合位点很容易被凝血酶和因子Xa切割,重链切割也得到了相同的结果。相比之下,凝血酶在精氨酸1689处对des-(741-1668)-factor VIII的切割速率低于因子Xa的类似切割速率,因子Xa的切割大概发生在精氨酸1721处。凝血酶在精氨酸1689处的切割速率也低于其他加工位点的切割速率。当des-(741-1668)-factor VIII被凝血酶激活时,因子Xa形成的初始速率与血浆来源的VIII因子被凝血酶或因子Xa激活时获得的速率相似。值得注意的是,des-(741-1668)-factor VIII被因子Xa激活的速率高于被凝血酶激活的速率。这些结果表明,VIII因子激活与精氨酸1689或精氨酸1721处的切割密切相关。对于des-(741-1668)-factor VIII与血管性血友病因子之间的相互作用,测定的解离常数(Kd)值为(0.8 ± 0.3) × 10⁻¹⁰ M,这与异二聚体VIII因子的解离常数相似。发现单链des-(741-1668)-factor VIII对因子IXa的亲和力为27 ± 6 nM。在豚鼠中评估了des-(741-1668)-factor VIII的体内回收率和半衰期。以50单位/千克体重的剂量输注des-(741-1668)-factor VIII后,VIII因子活性升高了1.0 ± 0.3单位/毫升。野生型VIII因子也得到了相同的回收率。发现des-(741-1668)-factor VIII的半衰期为3 ± 1小时,而异二聚体重组VIII因子的半衰期为4 ± 2小时。总之,des-(741-1668)-factor VIII表现出正常活性,在其融合位点很容易被凝血酶和因子Xa切割,与血管性血友病因子和因子IXa具有高亲和力,并且在豚鼠中的行为与异二聚体重组VIII因子相似。凭借这些特性,des-(741-1668)-factor VIII可能被证明对治疗甲型血友病患者的出血发作有用。